Fennec Pharmaceuticals (TSE:FRX) Shares Pass Above Fifty Day Moving Average - Time to Sell?

Key Points

• Fennec Pharmaceuticals stock price has crossed above its 50-day moving average, trading at C$11.93 compared to the average of C$11.89.
• The company's quick ratio is 10.17, while it has a market cap of C$332.04 million and a debt-to-equity ratio of -620.83.
• Insider Rostislav Christov Raykov sold 10,000 shares at C$11.71, indicating that insiders have sold a total of 13,246 shares worth $137,297 in the last quarter.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$11.89 and traded as high as C$12.20. Fennec Pharmaceuticals shares last traded at C$11.93, with a volume of 1,370 shares changing hands.

Fennec Pharmaceuticals Stock Down 1.1%

The firm has a 50-day simple moving average of C$11.89 and a 200 day simple moving average of C$10.39. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The company has a market capitalization of C$332.04 million, a PE ratio of -26.51 and a beta of 2.09.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov sold 10,000 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of C$11.71, for a total transaction of C$117,096.00. Insiders sold 13,246 shares of company stock worth $137,297 in the last three months. 16.20% of the stock is owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.